Business
Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo's Arguments and Director Slate
TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: ...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"Leading Independent Proxy Advisor ISS Recommends that Shareholders Vote the GREEN proxy FOR ALL MediPharm Director Nominees; REJECTS Apollo’s Arguments and Director SlateISS concludes that Apollo “has not presented a compelling case for change”\n\n\n\n TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“\n \n MediPharm\n \n ” or the “\n \n Company\n \n ”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that Institutional Shareholder Services (“\n \n ISS\n \n ”) published a report on May 30, 2025 (the “\n \n ISS Report\n \n ”) recommending that MediPharm shareholders vote the\n \n GREEN Proxy\n \n or voting instruction form\n \n FOR\n \n the Company’s nominees for the Board of Directors (the “\n \n Board\n \n ”) at the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the “\n \n Meeting\n \n ”).\n \n\n ISS is a leading independent proxy voting and corporate governance advisory firm whose recommendations are trusted by pension funds, investment managers, mutual funds, and other institutional shareholders. The ISS Report concludes:\n \n\n “\n \n As the dissident has not presented a compelling case for change, shareholders are recommended to vote FOR all management nominees.\n \n ”\n \n\n The ISS Report further recommended that MediPharm shareholders DO NOT VOTE on the gold dissident proxy card as Apollo did not provide a compelling case for change.\n \n\n Chris Taves, Chair of MediPharm, commented, “We are very pleased that an independent proxy advisory firm has taken the time to meet with both parties to hear our respective arguments, and has recommended voting in favour of management’s director nominees. Shareholders have been subjected to a large volume of information from both the Company and the dissident in recent weeks, and we believe the ISS Report reinforces our consistent position that Apollo has been flooding the market with misinformation and unsupportable statements. It is also encouraging that ISS has recognized the turnaround of our business that has been facilitated under the leadership of CEO David Pidduck. The Board truly believes that there is momentum in o...